Total submissions: 10
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000077523 | SCV000299791 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2016-09-08 | reviewed by expert panel | curation | Variant allele predicted to encode a truncated non-functional protein. |
Labcorp Genetics |
RCV000047891 | SCV000075904 | pathogenic | Hereditary breast ovarian cancer syndrome | 2015-09-07 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Truncating variants in BRCA1 are known to be pathogenic. This particular truncation has been reported in identical twins, both with ovarian cancer (PMID: 9406579). This variant is also known as 2711delA in the literature. This sequence change deletes 1 nucleotide from exon 10 of the BRCA1 mRNA (c.2594delA), causing a frameshift at codon 865. This creates a premature translational stop signal (p.Lys865Serfs*28) and is expected to result in an absent or disrupted protein product. |
ARUP Laboratories, |
RCV000505972 | SCV000602722 | pathogenic | not specified | 2017-01-25 | criteria provided, single submitter | clinical testing | |
Institute for Biomarker Research, |
RCV000578073 | SCV000679702 | pathogenic | Hereditary cancer-predisposing syndrome | 2017-07-12 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002477167 | SCV002793448 | pathogenic | Familial cancer of breast; Breast-ovarian cancer, familial, susceptibility to, 1; Pancreatic cancer, susceptibility to, 4; Fanconi anemia, complementation group S | 2021-12-05 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV000578073 | SCV004360266 | pathogenic | Hereditary cancer-predisposing syndrome | 2023-06-26 | criteria provided, single submitter | clinical testing | This variant deletes 1 nucleotide in exon 10 of the BRCA1 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in two siblings both affected with ovarian cancer (PMID: 9406579). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA1 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. |
Ambry Genetics | RCV000578073 | SCV005025766 | pathogenic | Hereditary cancer-predisposing syndrome | 2023-12-14 | criteria provided, single submitter | clinical testing | The c.2594delA pathogenic mutation, located in coding exon 9 of the BRCA1 gene, results from a deletion of one nucleotide at nucleotide position 2594, causing a translational frameshift with a predicted alternate stop codon (p.K865Sfs*28). This alteration has been identified in families with history of breast and ovarian cancers (Miesfeldt S et al. Cancer Genet Cytogenet, 1998 Jan;100:43-8). (Flaum N et al. Genet Med, 2022 Dec;24:2578-2586). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Sharing Clinical Reports Project |
RCV000077523 | SCV000109324 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2007-09-24 | no assertion criteria provided | clinical testing | |
Breast Cancer Information Core |
RCV000077523 | SCV000144485 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 1999-04-06 | no assertion criteria provided | clinical testing | |
Research Molecular Genetics Laboratory, |
RCV000047891 | SCV000587234 | pathogenic | Hereditary breast ovarian cancer syndrome | 2014-01-31 | no assertion criteria provided | research |